Abstract
We studied the penetration of etravirine and HIV shedding in the genital tract among 12 HIV-1-infected women receiving an etravirine-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median etravirine concentrations were 663 ng/ml in BP and 857 ng/ml in CVF, with a CVF/BP etravirine ratio of approximately 1.2. This good penetration of etravirine may contribute to the control of viral replication in the female genital tract.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / pharmacokinetics*
-
Anti-HIV Agents / therapeutic use*
-
Cervix Uteri / metabolism*
-
Female
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
Humans
-
Middle Aged
-
Nitriles
-
Pyridazines / pharmacokinetics*
-
Pyridazines / therapeutic use*
-
Pyrimidines
-
RNA, Viral / blood
-
RNA, Viral / genetics
-
Vagina / metabolism*
-
Virus Replication / drug effects
Substances
-
Anti-HIV Agents
-
Nitriles
-
Pyridazines
-
Pyrimidines
-
RNA, Viral
-
etravirine